Effects of diabetes mellitus on left ventricular function and deformation in patients with restrictive cardiomyopathies: a 3.0T CMR feature tracking study.
Cardiac magnetic resonance
Diabetes mellitus
Global peak strain
Restrictive cardiomyopathy
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
received:
01
09
2023
accepted:
13
10
2023
medline:
27
11
2023
pubmed:
21
11
2023
entrez:
21
11
2023
Statut:
epublish
Résumé
Diabetes mellitus (DM) is the most common metabolic disease worldwide and a major risk factor for adverse cardiovascular events, while the additive effects of DM on left ventricular (LV) deformation in the restrictive cardiomyopathy (RCM) cohort remain unclear. Accordingly, we aimed to investigate the additive effects of DM on LV deformation in patients with RCM. One hundred thirty-six RCM patients without DM [RCM(DM-)], 46 with DM [RCM (DM+)], and 66 age- and sex-matched control subjects who underwent cardiac magnetic resonance (CMR) scanning were included. LV function, late gadolinium enhancement (LGE) type, and LV global peak strains (including radial, circumferential, and longitudinal directions) were measured. The determinant of reduced LV global myocardial strain for all RCM patients was assessed using multivariable linear regression analyses. The receiver operating characteristic curve (ROC) was performed to illustrate the relationship between DM and decreased LV deformation. Compared with the control group, RCM (DM-) and RCM(DM+) patients presented increased LV end-diastolic index and end-systolic volume index and decreased LV ejection fraction. LV GPS in all three directions and longitudinal PDSR progressively declined from the control group to the RCM(DM-) group to the RCM(DM+) group (all p < 0.05). DM was an independent determinant of impaired LV GPS in the radial, circumferential, and longitudinal directions and longitudinal PDSR (β = - 0.217, 0.176, 0.253, and - 0.263, all p < 0.05) in RCM patients. The multiparameter combination, including DM, showed an AUC of 0.81(95% CI 0.75-0.87) to predict decreased LV GLPS and an AUC of 0.69 (95% CI 0.62-0.76) to predict decreased LV longitudinal PDSR. DM may have an additive deleterious effect on LV dysfunction in patients with RCM, especially diastolic dysfunction in RCM patients, indicating the importance of early identification and initiation of treatment of DM in patients with RCM.
Sections du résumé
BACKGROUND
BACKGROUND
Diabetes mellitus (DM) is the most common metabolic disease worldwide and a major risk factor for adverse cardiovascular events, while the additive effects of DM on left ventricular (LV) deformation in the restrictive cardiomyopathy (RCM) cohort remain unclear. Accordingly, we aimed to investigate the additive effects of DM on LV deformation in patients with RCM.
MATERIALS AND METHODS
METHODS
One hundred thirty-six RCM patients without DM [RCM(DM-)], 46 with DM [RCM (DM+)], and 66 age- and sex-matched control subjects who underwent cardiac magnetic resonance (CMR) scanning were included. LV function, late gadolinium enhancement (LGE) type, and LV global peak strains (including radial, circumferential, and longitudinal directions) were measured. The determinant of reduced LV global myocardial strain for all RCM patients was assessed using multivariable linear regression analyses. The receiver operating characteristic curve (ROC) was performed to illustrate the relationship between DM and decreased LV deformation.
RESULTS
RESULTS
Compared with the control group, RCM (DM-) and RCM(DM+) patients presented increased LV end-diastolic index and end-systolic volume index and decreased LV ejection fraction. LV GPS in all three directions and longitudinal PDSR progressively declined from the control group to the RCM(DM-) group to the RCM(DM+) group (all p < 0.05). DM was an independent determinant of impaired LV GPS in the radial, circumferential, and longitudinal directions and longitudinal PDSR (β = - 0.217, 0.176, 0.253, and - 0.263, all p < 0.05) in RCM patients. The multiparameter combination, including DM, showed an AUC of 0.81(95% CI 0.75-0.87) to predict decreased LV GLPS and an AUC of 0.69 (95% CI 0.62-0.76) to predict decreased LV longitudinal PDSR.
CONCLUSIONS
CONCLUSIONS
DM may have an additive deleterious effect on LV dysfunction in patients with RCM, especially diastolic dysfunction in RCM patients, indicating the importance of early identification and initiation of treatment of DM in patients with RCM.
Identifiants
pubmed: 37985989
doi: 10.1186/s12933-023-02033-w
pii: 10.1186/s12933-023-02033-w
pmc: PMC10662686
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317Subventions
Organisme : Postdoctoral Research Fund, West China Hospital, Sichuan University
ID : 2023HXBH040
Organisme : National Natural Science Foundation of China
ID : 82120108015
Organisme : National Natural Science Foundation of China
ID : 82371925
Informations de copyright
© 2023. The Author(s).
Références
Cardiovasc Diabetol. 2021 Jun 1;20(1):116
pubmed: 34074290
JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 1):1165-1173
pubmed: 30121266
Eur Heart J. 2022 Jan 31;43(4):333-341
pubmed: 34472567
JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):69-80
pubmed: 31202744
Cardiovasc Res. 2018 Jun 1;114(7):954-964
pubmed: 29432575
J Cardiovasc Magn Reson. 2018 Jul 30;20(1):53
pubmed: 30064457
J Am Coll Cardiol. 2003 Jul 16;42(2):328-35
pubmed: 12875772
Eur Heart J Cardiovasc Imaging. 2019 May 1;20(5):533-540
pubmed: 30247530
JACC Cardiovasc Imaging. 2016 Jun;9(6):680-6
pubmed: 27209101
Cardiovasc Diabetol. 2022 May 14;21(1):74
pubmed: 35568946
Circ Res. 2019 Jan 4;124(1):121-141
pubmed: 30605420
Eur Heart J. 2023 Oct 1;44(37):3503-3626
pubmed: 37622657
Cardiovasc Diabetol. 2023 May 31;22(1):129
pubmed: 37254111
Eur Heart J. 2022 Dec 1;43(45):4679-4693
pubmed: 36269634
J Am Coll Cardiol. 2009 Oct 13;54(16):1524-32
pubmed: 19815124
Eur J Prev Cardiol. 2022 Jan 11;28(16):1756-1766
pubmed: 33623980
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Eur Radiol. 2022 Apr;32(4):2594-2603
pubmed: 34779872
Heart Fail Rev. 2013 Mar;18(2):149-66
pubmed: 22453289
Cardiovasc Diabetol. 2020 Nov 24;19(1):197
pubmed: 33234149
Eur Radiol. 2022 Nov;32(11):7647-7656
pubmed: 35567605
Circ Res. 2020 May 22;126(11):1628-1645
pubmed: 32437305
Eur Heart J. 2008 Jan;29(2):270-6
pubmed: 17916581
Circ Res. 2018 Feb 16;122(4):624-638
pubmed: 29449364
Cardiovasc Diabetol. 2022 Jun 17;21(1):109
pubmed: 35715813
Cardiovasc Res. 2017 Mar 15;113(4):378-388
pubmed: 28395009
Cardiovasc Diabetol. 2021 Oct 23;20(1):212
pubmed: 34688280
Radiol Med. 2020 Nov;125(11):1072-1086
pubmed: 32970272
Eur Heart J Cardiovasc Imaging. 2017 Oct 1;18(10):1090-1121
pubmed: 28510718
Circ Res. 2017 Sep 15;121(7):819-837
pubmed: 28912185
JACC Cardiovasc Imaging. 2016 Nov;9(11):1267-1277
pubmed: 27568115
Eur Heart J. 2022 Aug 7;43(30):2817-2820
pubmed: 35933110
Rev Cardiovasc Med. 2022 Mar 17;23(3):108
pubmed: 35345275
Cardiovasc Diabetol. 2018 Oct 30;17(1):139
pubmed: 30373588
J Am Coll Cardiol. 2020 Feb 25;75(7):750-758
pubmed: 32081284